LQDA ▲ +3.5% - Liquidia Corporation $LQDA - FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis Liquidia Corporation shares rose 3.5% after the FDA granted Fast Track designation to its drug YUTREPIA® for treating Raynaud's phenomenon associated with systemic sclerosis. Fast Track status accelerates the FDA review process and represents regulatory validation of the therapy's potential to address an unmet medical need in this patient population. 03-SEP-2026 07:30 AM ET